Human papillomavirus type 16 antagonizes IRF6 regulation of IL-1β.

Référence:

PLoS Pathog. 2018 Aug 8

Auteurs:

Ainouze M(1), Rochefort P(1), Parroche P(1), Roblot G(1), Tout I(1), Briat F(1), Zannetti C(1), Marotel M(1), Goutagny N(2), Auron P(3), Traverse-Glehen A(2), Lunel-Potencier A(5), Golfier F(5), Masson M(4), Robitaille A(5), Tommasino M(5), Carreira C(5), Walzer T(1), Henry T(1), Zanier K(4), Trave G(4), Hasan UA(1).

Abstract:

Human papillomavirus type 16 (HPV16) and other oncoviruses have been shown to block innate immune responses and to persist in the host. However, to avoid viral persistence, the immune response attempts to clear the infection. IL-1β is a powerful cytokine produced when viral motifs are sensed by innate receptors that  are members of the inflammasome family. Whether oncoviruses such as HPV16 can activate the inflammasome pathway remains unknown. Here, we show that infection of human keratinocytes with HPV16 induced the secretion of IL-1β. Yet, upon expression of the viral early genes, IL-1β transcription was blocked. We went on  to show that expression of the viral oncoprotein E6 in human keratinocytes inhibited IRF6 transcription which we revealed regulated IL-1β promoter activity. Preventing E6 expression using siRNA, or using E6 mutants that prevented degradation of p53, showed that p53 regulated IRF6 transcription. HPV16 abrogation of p53 binding to the IRF6 promoter was shown by ChIP in tissues from  patients with cervical cancer. Thus E6 inhibition of IRF6 is an escape strategy used by HPV16 to block the production IL-1β. Our findings reveal a struggle between oncoviral persistence and host immunity; which is centered on IL-1β
regulation.

Lien vers la publication

 

Affiliations des auteurs:

Ainouze M(1), Rochefort P(1), Parroche P(1), Roblot G(1), Tout I(1), Briat F(1), Zannetti C(1), Marotel M(1), Goutagny N(2), Auron P(3), Traverse-Glehen A(2), Lunel-Potencier A(5), Golfier F(5), Masson M(4), Robitaille A(5), Tommasino M(5), Carreira C(5), Walzer T(1), Henry T(1), Zanier K(4), Trave G(4), Hasan UA(1).

(1)Centre International de recherche en Infectiologie, CIRI, Inserm, U1111, Lyon, France. Université Claude Bernard Lyon 1, Lyon, France.CNRS, UMR5308, Lyon, France. École Normale Supérieure de Lyon, Univ Lyon, France. Hospices Civils de Lyon, France.
(2)Cancer Research Centre of Lyon, INSERM U1052-CNRS UMR5286, Lyon, France.
(3)Duquesne University, Pittsburgh, Pennsylvania, United States of America.
(4)IGBMC, UMR 7104-U964, ILLKIRCH, France.
(5)Hospices Civils de Lyon, France.
(9)IARC, Lyon, France.

NOS TUTELLES ET PARTENAIRES